about
Guidelines for the use and interpretation of assays for monitoring autophagySIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancerRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerHow will we recruit, train, and retain physicians and scientists to conduct translational cancer research?Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineGenes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signalingHER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathwaysMUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouseSalt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic NicheA Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells.American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.CA125/MUC16 is dispensable for mouse development and reproductionLoss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cellsThe biology of ovarian cancer: new opportunities for translationDevelopment of a multimarker assay for early detection of ovarian cancer.Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cellsProteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cellsEarly detection of ovarian cancerChemotherapy: A new standard combination for recurrent ovarian cancer?ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins.Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome.Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.Potential markers that complement expression of CA125 in epithelial ovarian cancer.Translational research--traffic on the bridge.Activating and propagating polyclonal gamma delta T cells with broad specificity for malignanciesNational Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancerOvarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells.General keynote: molecular therapeutics and pharmocogenomics.Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.Epigenetic regulation of ARHI in breast and ovarian cancer cells.Progress in the management of gynecologic cancer: consensus summary statement.The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis.Clinically relevant microRNAs in ovarian cancer
P50
Q21996341-C909AD68-4994-4337-B241-1957F006BA48Q24295146-35D35695-D1D9-4689-B9FA-AD946163E45DQ26780387-94448417-734E-4ED2-B01B-1EAEDB7AD016Q27026431-53963F10-4BCB-4965-A54E-5526F2003BDBQ28079118-83928A58-C1FE-4690-A6B4-C523B5668F9EQ28289659-4FEBA4B0-A934-4F95-A376-CB3D77BE4361Q28299421-2FD21A7A-347B-46AA-9CAC-C795C313024DQ28594087-20466E44-A745-42B6-94F1-51E96279122DQ29147420-622F77B4-DD16-4E95-8080-9627375AB25FQ33220842-68A7E56F-3232-4260-B7A7-E628DD0A1FC8Q33303529-59D8F20C-160B-4501-AA16-DCFAAD10234CQ33415034-BC3A81BF-9A20-4B2B-B682-D3096DB40720Q33566765-B8BF4894-BFFC-4A36-BB08-64142C061BBCQ33622369-9E225778-387C-40EF-BF29-228F2379C70AQ33813724-4F5FBCE7-8054-4381-8E84-73DBC018E899Q33817285-AB744680-F921-4A8E-8726-90E8BDEC17A8Q33858449-DD8BCEFD-8ADE-46E5-B5F2-F96DC68589EEQ33862961-0A53D8C7-F1EB-4C85-8452-1FC31B59F8FFQ33878937-0568FF21-E378-4718-95EA-0FB879C81CDBQ33946840-99941A84-53FD-4A5B-9EDA-F6641040FAAEQ33980966-EA8B63E9-878E-461E-BD8B-A2335B273A90Q34094731-CC829110-F782-47E4-909F-19A69B1875ECQ34206001-62081922-2185-426F-B0B2-F01C713AACB4Q34282473-1AC32229-0499-431B-BABA-F6CDFF8280A8Q34303319-D03A56A3-0238-43FD-96D4-BD381373AB27Q34420393-AE842CC7-FC93-46DF-B090-FCE13310EBD4Q34439240-CB5CB196-A876-4EC0-A818-ECA9E00EEFE8Q34479826-7F3B8EAF-A37E-451C-B4F1-12C77FF93016Q34517192-B7703CF3-0BBF-47AD-ABE6-3CEE32DAFB8EQ34601116-814CF0DF-6D68-4789-9150-56B24E8720B1Q34672941-FC969CBD-FCD0-4F9C-8C74-E7BA2F9EC6D8Q34711457-A3B327A3-8052-4F62-81FD-0464A573343CQ34895083-F7BDD28F-CCEC-4644-8222-8884635CBB76Q34992198-1DCD8B33-5802-4CD4-AEB1-69B86669A236Q35066002-E2EF3788-BC98-4341-BCD4-C3A20B7BF769Q35109281-C5FDC633-749A-4D06-A307-4D91C03D332EQ35118540-855D13B3-796F-4094-B251-714630394AF8Q35125921-A5705DD9-765B-4FBE-BF8F-72F38C9AD3DAQ35133880-738C0D80-0D69-489B-9716-4208E37DCCAEQ35204609-718B541D-0533-48F3-BFF7-5275D5223510
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Robert C Bast
@nl
Robert C Bast
@sl
Robert C. Bast
@en
Robert C. Bast
@es
type
label
Robert C Bast
@nl
Robert C Bast
@sl
Robert C. Bast
@en
Robert C. Bast
@es
prefLabel
Robert C Bast
@nl
Robert C Bast
@sl
Robert C. Bast
@en
Robert C. Bast
@es
P1053
E-6585-2011
P106
P21
P31
P3829
P496
0000-0003-4621-8462